# Glycyrrhetinic Acid-Effect on Serum Potassium and Insulin Resistance in Dialysis Patients

> **NCT00384384** · PHASE2 · COMPLETED · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 24 (—)

## Conditions studied

- End Stage Renal Disease

## Interventions

- **DRUG:** oral 18B Glycyrrhetinic acid versus placebo

## Key facts

- **NCT ID:** NCT00384384
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** —
- **Final completion:** 2007-04
- **Target enrollment:** 24 (—)
- **Last updated:** 2011-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00384384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00384384, "Glycyrrhetinic Acid-Effect on Serum Potassium and Insulin Resistance in Dialysis Patients". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00384384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*